These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30206174)

  • 61. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.
    Khurana S; Fuentes S; Coyle EM; Ravichandran S; Davey RT; Beigel JH
    Nat Med; 2016 Dec; 22(12):1439-1447. PubMed ID: 27798615
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design of universal Ebola virus vaccine candidates via immunofocusing.
    Xu D; Powell AE; Utz A; Sanyal M; Do J; Patten JJ; Moliva JI; Sullivan NJ; Davey RA; Kim PS
    Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2316960121. PubMed ID: 38319964
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.
    Fan P; Chi X; Liu G; Zhang G; Chen Z; Liu Y; Fang T; Li J; Banadyga L; He S; Yu C; Qiu X; Chen W
    MAbs; 2020; 12(1):1742457. PubMed ID: 32213108
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease.
    Babirye P; Musubika C; Kirimunda S; Downing R; Lutwama JJ; Mbidde EK; Weyer J; Paweska JT; Joloba ML; Wayengera M
    BMC Infect Dis; 2018 Oct; 18(1):498. PubMed ID: 30285648
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
    Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Lee JE; Fusco ML; Hessell AJ; Oswald WB; Burton DR; Saphire EO
    Nature; 2008 Jul; 454(7201):177-82. PubMed ID: 18615077
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.
    Iba Y; Fujii Y; Ohshima N; Sumida T; Kubota-Koketsu R; Ikeda M; Wakiyama M; Shirouzu M; Okada J; Okuno Y; Kurosawa Y; Yokoyama S
    J Virol; 2014 Jul; 88(13):7130-44. PubMed ID: 24719430
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantification of Filovirus Glycoprotein-Specific Antibodies.
    Furuyama W; Miyamoto H; Yoshida R; Takada A
    Methods Mol Biol; 2017; 1628():309-320. PubMed ID: 28573631
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
    J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spontaneous Mutation at Amino Acid 544 of the Ebola Virus Glycoprotein Potentiates Virus Entry and Selection in Tissue Culture.
    Ruedas JB; Ladner JT; Ettinger CR; Gummuluru S; Palacios G; Connor JH
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539437
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding.
    Ripoll DR; Mitchell DAJ; Dupuy LC; Wallqvist A; Schmaljohn C; Chaudhury S
    Hum Vaccin Immunother; 2017 Dec; 13(12):2953-2966. PubMed ID: 28922082
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody.
    Wang Y; Liu Z; Dai Q
    Virus Res; 2014 Aug; 189():254-61. PubMed ID: 24930448
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.
    Ilinykh PA; Shen X; Flyak AI; Kuzmina N; Ksiazek TG; Crowe JE; Bukreyev A
    J Virol; 2016 Apr; 90(8):3890-3901. PubMed ID: 26819310
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment.
    Landeras-Bueno S; Oda SI; Norris MJ; Li Salie Z; Guenaga J; Wyatt RT; Saphire EO
    mBio; 2019 Jul; 10(4):. PubMed ID: 31337716
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.